ACE2 and infection: Since angiotensin-converting enzyme 2 (ACE2) in the RAS is the entry of SARS-CoV-2 in the cell initiating infection, ARBs and bisartans, and in particular BV6 (bearing two biphenyl tetrazoles), were investigated as possible antivirals to treat COVID-19 disease furthermore to its antihypertensive potential [13,14].